Remibrutinib (Rhapsido) for Chronic Spontaneous Urticaria
Abstract
The FDA has approved remibrutinib (Rhapsido – Novartis), an oral Bruton's tyrosine kinase (BTK) inhibitor, for treatment of chronic spontaneous urticaria in adults who remain symptomatic despite H1-antihistamine treatment. Remibrutinib is the first oral drug to be approved in the US for this indication.
Fields of Study & Subjects
Urticaria and Related Conditions
Coagulation
Bradykinin
Polyphosphates
and Angioedema
Drug-Induced Adverse Reactions
Publication details
- Journal / source
- The medical letter on drugs and therapeutics/The medical letter
- Volume
- 68
- Issue
- 1745
- Pages
- 3–6
- Publication date
- 5 January 2026
- Language
- EN